Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-26-005370
Filing Date
2026-01-20
Accepted
2026-01-20 07:43:38
Documents
2
Period of Report
2026-01-20

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0273285-6k_lakeshore.htm 6-K 10842
2 PRESS RELEASE - LAKESHORE BIOPHARMA TO HOLD EXTRAORDINARY GENERAL MEETING OF SHA ea027328502ex99-1_lakeshore.htm EX-99.1 13567
  Complete submission text file 0001213900-26-005370.txt   25767
Mailing Address BUILDING NO. 2, 38 YONGDA ROAD DAXING BIOMEDICAL INDUSTRY PARK DAXING DISTRICT, BEIJING F4 102629
Business Address BUILDING NO. 2, 38 YONGDA ROAD DAXING BIOMEDICAL INDUSTRY PARK DAXING DISTRICT, BEIJING F4 102629 17327133678
LakeShore Biopharma Co., Ltd. (Filer) CIK: 0001946399 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 0331
Type: 6-K | Act: 34 | File No.: 001-41598 | Film No.: 26541146
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)